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Aim: Lower respiratory infections in infancy may be associated with lung function deficits in
adulthood. Our aim was to evaluate lung function, with a special focus on irreversible airway
obstruction, thirty years after bronchiolitis or pneumonia in infancy.
Methods: In 1981e1982, 83 children under two years of age were hospitalized for bronchiolitis
and 44 for pneumonia at Kuopio University Hospital, Finland. In 2010, 47 bronchiolitis patients,
22 pneumonia patients and 138 controls attended the study, including spirometry before (pre-
BD) and after bronchodilatation (post-BD). The measured indices were forced vital capacity
(FVC) and forced expiratory volume in one second (FEV1), that were presented as % of pre-
dicted value (FVC% and FEV1%). FEV1/FVC was presented as both absolute FVC/FEV1-ratio
and % of predicted (FEV1/FVC%). Irreversible airway obstruction was defined as post-BD
FEV1/FVC% below 88% of predicted (FEV1/FVC% <88%) according to Finnish reference values
or FEV1/FVC-ratio below fifth percentile (FEV1/FVC <5th percentile), according to Global Lung
Function Initiative reference values.
Results: All lung function indices were lower in former bronchiolitis patients and pre- and post-
BD FEV1% in pneumonia patients, compared to controls. 21% of bronchiolitis (OR, 95%CI; 5.59,
1.72e18.21) and 9% of pneumonia patients (2.24, 0.34e13.56) had FEV1/FVC% <88% compared
to controls (4%). Likewise 7 (15%) of bronchiolitis (7.07, 1.33e37.22) and 1 (5%) of pneumonia
patients (1.73, 0.12e24.77) had FEV1/FVC <5th percentile compared to controls 2 (1%).t of Pediatrics, Kuopio University Hospital, P.O. Box 100, FI-70029 Kuopio, Finland. Tel.: þ358 50
h.fi (K. Backman).
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Irreversible airway obstruction after bronchiolitis 219Conclusion: Evidence of reduced lung function was present 30 years after hospitalization for
bronchiolitis or pneumonia in infancy. Irreversible airway obstruction after severe bronchiolitis
in infancy suggests permanent, structural alterations in airways.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
The association between lower respiratory infections (LRI)
like bronchiolitis and pneumonia in infancy and increased
risk of lung function disorders in childhood has been
demonstrated in several studies [1,2], including a recent
systematic review and meta-analysis on long-term sequelae
of early childhood pneumonia [3]. In addition, LRI’s in in-
fancy have been associated with subsequent lung function
disorders even in adulthood [4e8]. In the Swedish post-
bronchiolitis follow-up study, airway obstruction was
found in both pre- and post-bronchodilator measurements
at the age of 17e18 years indicating that the obstruction
was irreversible [7].
In birth cohort studies, reduced lung function has been
present in infancy before any respiratory infection, and
evidently reduced lung function predisposes an infant to
both early childhood LRI’s and subsequent wheezing
[9e12]. Moreover, subjects with reduced lung function in
early life were at an increased risk for permanent bronchial
obstruction at the age of 22 years, even in the absence of
any persistent symptoms [13].
We have followed a group of patients hospitalized for
bronchiolitis or pneumonia in early childhood in
1981e1982, and found an increased risk of both asthma and
lung function disorders up to the age of 18e20 years [8]. In
2010, when the study subjects were 28e31 years old, hos-
pitalization for bronchiolitis in infancy was associated with
an increased risk for asthma and hospitalization for both
bronchiolitis and pneumonia with an impaired quality of life
in adulthood [14].
In the present study, we evaluated lung function by using
flow volume spirometry (FVS), including both pre-
bronchodilator (pre-BD) and post-bronchodilator (post-BD)
measurements in these former infantile bronchiolitis and
pneumonia patients, and in matched population controls,
at the age of 28e31 years. We hypothesized that perma-
nently reduced lung function, and irreversible obstruction
in particular, may be present in young adults after severe
LRI in infancy. If the hypothesis is true, LRI in early child-
hood may predispose infants even to chronic obstructive
pulmonary disease (COPD) in later adulthood. The aim of
the study was to evaluate if reduced lung function and
irreversible bronchial obstruction are present at the age of
28e31 years after bronchiolitis or pneumonia in infancy.Material and methods
Study subjects
In 1981e1982, altogether 127 patients were hospitalized for
bronchiolitis (N Z 83) or pneumonia (N Z 44) at less thantwo years of age in the Department of Pediatrics, Kuopio
University Hospital, Finland. Data on wheezing history,
presence of asthma, and risk factors for asthma were
collected at repeated control visits until the age of 18e20
years [8,15]. As published recently [14], an invitation to the
study and a written questionnaire were sent to 122 study
subjects with current addresses available. The question-
naire included inquiries about previous asthma diagnoses
and current respiratory symptoms, like wheezing episodes,
and medication used for asthma during the preceding 12
months [14].
In 2010, 48 (57.8%) former bronchiolitis and 22 (50.0%)
former pneumonia patients attended the clinical study,
which consisted of a doctoral interview and examination,
FVS including both pre-BD and post-BD measurements, and
monitoring two-week home peak expiratory flow (PEF). An
invitation to the study was also sent to 488 population-
based controls born in the area of Kuopio University Hos-
pital and they were matched for sex and age (birth month).
Four control subjects, who answered the questionnaire and
had been hospitalized for lower respiratory tract infection
at less than 24 months of age, were excluded. Altogether
138 (28.3%) of the invited controls attended the clinical
study [14].
Acceptable FVS was obtained from all but one of the
study subjects and from all controls. Thus, 47 former
bronchiolitis patients, 22 former pneumonia patients, and
138 controls formed the material of the present lung
function study.
Presence of asthma and smoking
There were significant differences in current asthma and
current smoking between the two study groups (bronchio-
litis in infancy, pneumonia in infancy) and population con-
trols [14]. Seventeen (36.2%) former bronchiolitis patients,
5 (22.7%) former pneumonia patients and 20 (14.5%) con-
trols had asthma [14]. Asthma diagnosis was settled based
on previous doctor-diagnosed asthma, usage of asthma
medication, asthma-presumptive symptoms, and a patho-
logical result in the home PEF monitoring [14]. Fourteen
(29.8%) former bronchiolitis patients, 10 (45.5%) former
pneumonia patients and 17 (12.3%) controls were current
daily smokers (one cigarette or more smoked daily during
the preceding 12 months) [14]. The median of the smoked
pack-years was 0.1 (Range 0.0e25.0, p Z 0.027) in the
bronchiolitis group and 0.5 (0.0e22.5, 0.064) in the pneu-
monia group, compared to 0.0 (0.0e25.0) in controls.
Lung function data
Baseline lung function was measured with a Medikro
SpiroStar USB spirometer (Medikro, Kuopio, Finland) using
220 K. Backman et al.Spiro 2000, Software version 2.2. FVS was performed and
the results were reported according to ATS (American
Thoracic Society) and ERS (European Respiratory Society)
standards [16]. At a minimum, 3 technically acceptable
measurements were required, and if needed, the mea-
surements were repeated up to 8 times. The measured
indices were forced vital capacity (FVC) and forced expi-
ratory volume in one second (FEV1). FVC and FEV1 were
presented as percentages of the means of age- and sex-
specific, height-related reference values (FVC% and
FEV1%) [17]. FEV1/FVC is presented as both absolute (FEV1/
FVC-ratio) and age- and sex-specific, height-related (% of
predicted) values (FEV1/FVC%) [17]. FVS was performed
before (pre-BD values) and 15 min after (post-BD values)
inhalation of 400 mg salbutamol (Ventoline Evohaler 0.1 mg/
dos, GlaxoSmithKline).
Irreversible airway obstruction was defined as post-BD
FEV1/FVC% below 88% of predicted value (FEV1/FVC% <88%)
according to the Finnish age- and sex-specific, height-
related cut-off limit that was settled at the level of 2
standard deviations (SD) (Z-score 1.96) in Finnish non-
selected adults [17].
Since Finnish references are old, and newer up-to-dated
national references are not available, we defined the
irreversible airway obstruction also by using the recently
published, multi-ethnic, age-, sex- and height-adjusted,
Global Lung Function Initiative 2012 (GLI 2012) limits for
abnormal FEV1/FVC-ratio [18]. On the basis of this crite-
rion, irreversible obstruction was considered to be present,
if post-BD FEV1/FVC-ratio was below 5th percentile (lower
limit of normality), corresponding z-score 1.64 (FEV1/FVC
<5th percentile) [18].
Statistics
Data were analyzed by using SPSS 19.0 software (SPSSInc.
Chicago, IL, USA). The results are given as means, odds
ratios (OR) and 95% confidence intervals (95%CI) or p-
values. Analysis of variance (ANOVA) adjusted for asthma
and current daily smoking was used in the analysis of
continuous data, and logistic regression including group
(bronchiolitis, pneumonia, control), asthma (yes, no) and
current smoking (yes, no) for categorized data.
Ethics
The study was approved by the Ethics Committee of the
Pohjois-Savo Health-Care District. A written consent was
obtained from all study subjects.
Results
Pre-BD and post-BD FVC%, FEV1%, FEV1/FVC% and FEV1/
FVC-ratio were lower in the former bronchiolitis patients
than in controls (Table 1). Instead, the former pneumonia
patients differed from controls only for pre-BD and post-BD
FEV1% (Table 1). There were no significant differences be-
tween bronchiolitis and pneumonia groups in any lung
function indices (Data not shown). When comparing the
improvements of FEV1 after BD, no significant differences
were found between the three study groups (Table 1).To investigate whether the presence of asthma could
explain the differences in lung function, we performed the
analysis also after excluding the asthma patients. In this
subgroup analysis, non-asthmatic former bronchiolitis pa-
tients had lower post-BD FEV1%, FEV1/FVC% and FEV1/FVC-
ratio than controls, and non-asthmatic former pneumonia
patients had lower post-BD FEV1% and FEV1/FVC% than
controls (Table 2).
Post-BD FEV1/FVC% was below 88% of predicted value in
10 (21%) former bronchiolitis patients, 2 (9%) former
pneumonia patients and 5 (4%) controls. The respective
figures for FEV1/FVC <5th percentile, according to the GLI
2012 reference values, were 7(15%), 1(5%) and 2(1%). The
group (bronchiolitis, pneumonia, control), asthma and
current smoking were included as covariates in the logistic
regression. Belonging to the bronchiolitis group was an
independently significant risk factor for irreversible airway
obstruction by the Finnish, and belonging to the bronchio-
litis group and the presence of current asthma by the GLI
2012 criteria (Table 3).Discussion
There are three main results in the present study. First, the
study subjects hospitalized for bronchiolitis or pneumonia
in infancy presented with lower lung function than
population-based controls at 28e31 years of age. Second,
21% of the former bronchiolitis patients had irreversible
airway obstruction according to the Finnish reference
values and 15% by the international GLI 2012 reference
values. Third, hospitalization for bronchiolitis in infancy
was a significant risk factor for irreversible airway
obstruction in this prospective 30-year post-bronchiolitis
study.
In the bronchiolitis group, both pre- and post-BD lung
function indices were, on average, lower than in controls.
The significant differences in post-BD FEV1/FVC% indicated
the irreversibility of airway obstruction in the bronchiolitis
group. Previous prospective post-bronchiolitis studies have
demonstrated that lung function may remain reduced until
early adulthood after bronchiolitis in infancy [6e8], with
some evidence for irreversible airway obstruction [6,7]. In
the present study, evidence for reduced lung function and
irreversible airway obstruction after bronchiolitis in infancy
was found at 28e31 years of age.
In the pneumonia group, pree and posteBD FEV1%, but
not FEV1/FVC% or FEV1/FVC-ratio, were lower than in
controls. In the birth cohort from Tucson, Arizona, radio-
logically confirmed pneumonia at less than 3 years of age
was associated with persistent wheezing at the age of six
years, and with an increased risk of asthma and reduced
lung function at the age of 11 years [19]. In a recent sys-
tematic review and meta-analysis, restrictive pulmonary
disease was the most common sequela after pneumonia in
early childhood [3]. In the present study, post-BD FVC%,
which measures lung volume and reflects the restrictive
properties of the lungs, was significantly lower in the
former bronchiolitis patients than in the controls. However,
the difference between controls and former pneumonia
patients was not significant, mainly due to the small num-
ber of cases.
Table 1 Pre- and post-bronchodilator lung function at the age of 28e31 years after bronchiolitis or pneumonia in infancy
compared to controls, presented as means and 95% confidence intervals (95%CI).
Lung function parameter Bronchiolitis N Z 47 p-valuef Pneumonia N Z 22 p-valuef Controls N Z 138
FVC%b
Pre-BDa 98 (94e101) 0.025 98 (93e106) 0.099 102 (100e104)
Post-BDa 98 (94e101) 0.026 98 (93e102) 0.095 102 (100e103)
FEV1%
c
Pre-BDa 86 (83e90) <0.001 89 (85e93) 0.006 96 (94e98)
Post-BDa 90 (87e93) <0.001 93 (88e97) 0.003 100 (99e101)
FEV1/FVC%
d
Pre-BDa 89 (86e92) <0.001 91 (88e95) 0.143 95 (93e96)
Post-BDa 93 (90e95) <0.001 95 (92e99) 0.093 99 (97e100)
FEV1/FVC-ratio
Pre-BDa 0.75 (0.73e0.78) 0.001 0.78 (0.75e0.81) 0.324 0.80 (0.79e0.81)
Post-BDa 0.78 (0.76e0.81) <0.001 0.81 (0.78e0.84) 0.255 0.83 (0.82e0.84)
FEV1 BD response
e
4.3 (3.5e5.2) 0.603 4.3 (2.2e6.3) 0.881 4.3 (3.5e5.2)
a Pre-BD, pre-bronchodilator; post-BD, post-bronchodilator.
b FVC%, forced vital capacity (% of predicted value).
c FEV1%, forced expiratory volume in one second (% of predicted value).
d FEV1/FVC% means FEV1/FVC ratio presented as % of predicted value.
e Change in % between pre- and post-BD FEV1 values.
f Analysis of variance, adjusted for asthma and current daily smoking, bronchiolitis group vs. controls, and pneumonia group vs.
controls.
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ratory infections have had a close association with future
respiratory morbidity and diminished lung function [4,5].
However, the independent role of early respiratory infec-
tion has remained unresolved. Low lung function at birth
predisposes infants to LRI’s and wheezing in early childhood
[9e12], and those who had low lung function at birth pre-
sented with lower than normal lung function through
childhood into adulthood [13]. This does not exclude the
fact that unfavorable postnatal factors, such as exposure to
tobacco smoke or LRIs during the first years of life may
further worsen the reduced lung function [13,20,21]. In the
present study, we were able to document the link between
hospitalization for LRI in infancy and lung function impair-
ment in adulthood.
Smoking is a well-known major risk factor for both
asthma, COPD, and corresponding lung function disorders
[22e24]. In the present study smoking was common,Table 2 Post-bronchodilator FEV1%, FEV1/FVC% and FEV1/FVC
groups.
Lung function parameter Bronchiolitis N Z 30 p-valued
FEV1%
b
Post-BDa 91 (88e95) <0.001
FEV1/FVC%
c
Post-BDa 93 (90e96) <0.001
FEV1/FVC-ratio
Post-BDa 0.79 (0.76e0.82) <0.001
a Post-BD, post-bronchodilator.
b FEV1%, forced expiratory volume in one second (% of predicted va
c FEV1/FVC% means FEV1/FVC-ratio presented as % of predicted val
d Analysis of variance, adjusted with current daily smoking, bronchreported by 29.8% of the former bronchiolitis and 45.5%
of the former pneumonia patients. The figure in the
controls, 12.3%, was rather similar to the Finnish age-
specific population [25]. Maternal smoking during preg-
nancy is one of the most important risk factors for
reduced lung function at birth and subsequent wheezing
[10,22,26e28]. In addition, children exposed to passive
smoking have an increased risk for active smoking in
later life [29]. Thus, children of smoking mothers have an
increased risk for respiratory infections in infancy and an
increased risk for smoking in adulthood, which may
explain the surprisingly high rates of smoking in our
cohort. Despite the commonness, the effects of smoking
seemed to be minor. This finding is in line with the pre-
vious observation that the effect of childhood respiratory
infections on lung function in young adulthood was not
substantially further increased by smoking [4]. At the age
of 28e31 years, the cumulative exposure to tobacco-ratio in the study subjects without asthma in three study
Pneumonia N Z 17 p-valued Controls N Z 118
95 (91e98) 0.022 100 (99e102)
95 (93e97) 0.027 99 (98e100)
0.81 (0.8e0.83) 0.110 0.84 (0.83e0.85)
lue).
ue.
iolitis group vs. controls and pneumonia group vs. controls.
Table 3 Logistic regression: hospitalization for bronchiolitis or pneumonia in infancy, current asthma and current daily
smoking at 28e31 years of age as risk factors for irreversible airway obstruction.
Risk factor for irreversible
airway obstruction
FEV1/FVC% <88%
a
N Z 17
Adjusted ORb (95%CI) FEV1/FVC <5th
percentilec
N Z 10
Adjusted ORb (95%CI)
Bronchiolitis group 10/47 (21%) 5.59 (1.72e18.21) 7/47 (15%) 7.07 (1.33e37.22)
Pneumonia group 2/22 (9%) 2.24 (0.34e13.56) 1/22 (5%) 1.73 (0.12e24.77)
Current daily smoking 15/41 (12%) 1.21 (0.36e4.04) 4/41 (10%) 2.22 (0.49e10.05)
Asthma 8/42 (19%) 2.83 (0.97e8.30) 7/42 (17%) 7.56 (1.75e32.6)
a Post-bronchodilator FEV1/FVC-ratio below 88% of predicted value.
b All variables (group, current daily smoking and asthma) are included in the same logistic regression model.
c FEV1/FVC - ratio below 5th percentile lower limit of normality (GLI 2013 criteria).
222 K. Backman et al.smoke is still low. In smokers, a greater than age-related
decline in lung function will occur from the fourth decade
of life onwards [22]. We repeated all analyses as adjusted
for ever smoked pack-years, and the results did not
change.
At least one fourth of the COPD cases are not related to
tobacco smoking [30]. Asthma is a well-documented risk
factor for permanent lung function impairment, including
irreversible bronchial obstruction [31], and COPD [5]. In the
present study, the analyses were adjusted for current
asthma. In addition, we made a subgroup analysis in the
study subjects with no current asthma, and the results were
similar to the main analyses. The results are in agreement
with those of the Swedish study after RSV bronchiolitis at
under 12 months of age, in which symptom-free former
bronchiolitis patients also had lower lung function than
controls [6].
An important finding of the present study is that 21% of
former bronchiolitis patients had irreversible airway
obstruction, when the Finnish age- and gender adjusted,
height-related, population-based criterion for airway
obstruction (FEV1/FVC% <88%) was used. On the basis of
this criterion, 2.5% of the healthy population has FEV1/
FVC% below the settled limit. Since the Finnish references
are old, we analyzed the FEV1/FVC-ratio also by using the
recently published, multi-ethnic, age-, sex- and height-
adjusted GLI 2012 criteria for airway obstruction (FEV1/
FVC <5th percentile) [18] and irreversible airway
obstruction was present in 14.5%. According to this cri-
terion, 5.0% of the non-selected population has FEV1/FVC-
ratio below the settled limit. Belonging to the bronchio-
litis group remained as a significant risk factor for irre-
versible airway obstruction, regardless of the used
definition. Thus, hospitalization for bronchiolitis in in-
fancy is a significant risk factor for irreversible airway
obstruction at 30 years of age.
As maximal lung function is reached in early adulthood,
subjects who start adult life with a lower FEV1/FVC-ratio
may attain the threshold of COPD earlier during normal
lung ageing than those starting with a higher FEV1/FVC-
ratio [32]. We found preliminary evidence that subjects
with bronchiolitis in infancy have more often obstructive
airways in the early middle age, compared to controls
with no history of LRI hospitalization in infancy. These
alterations in airways may progress to COPD during normal
lung ageing.The strengths of the present study are the long follow-up
time, a careful collection of clinical data in early child-
hood, and a well-conducted clinical study at the age of
28e31 years. Since the former bronchiolitis and pneumonia
patients lived in different parts of the country, the clinical
study was performed by the same researchers at 12
outpatient clinics. In all cases, FVS was performed by a
trained respiratory nurse of the research group, using the
same spirometer and following the current international
standards [16]. The main shortcoming of the study was the
small number of subjects. We were able to clinically
examine 70 (57.3%) of the 122 study subjects with a current
address available. The participation rate in the control
group was even lower. The asthma prevalence of the con-
trols was 15%, which is higher than the 5% asthma preva-
lence in non-selected Finnish young adults of the same age
[33]. The prevalence of irreversible airway obstruction in
controls (4%), defined as post-BD FEV1/FVC% <88% was
close to 2.5% in the non-selected Finnish adult population.
Lung function was not measured before any early childhood
infections, and therefore our present study was unable to
answer the question of whether or not the low lung function
in infancy has predisposed infants to early-life LRI, and
further, to low lung function at the age of 28e31years.
In conclusion, evidence of reduced lung function was
present 30 years after hospitalization for bronchiolitis or
pneumonia in infancy. Irreversible airway obstruction after
severe bronchiolitis in infancy suggests permanent, struc-
tural alterations in airways. In adjusted analyses, hospi-
talization for bronchiolitis in infancy was a more significant
risk factor for irreversible airway obstruction at the age of
28e31 years than current asthma or current smoking.Conflict of interest statement
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